Application | Comment | Organism |
---|---|---|
pharmacology | the GCN5-NF-kB pathway is a potentialmolecular target for stem cell mediated regenerative medicine and the treatment of metabolic bone diseases such as osteoporosis | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Mus musculus C57BL/6 | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
bone marrow | decreased GCN5 in osteoporotic bone marrow | Mus musculus | - |
additional information | expression of GCN5 is decreased significantly in the bone tissue sections of ovariectomized mice or aged mice | Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
Gcn5 | - |
Mus musculus |
general control nonderepressible 5 | - |
Mus musculus |
HAT | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
malfunction | knockdown of GCN5 inhibits the osteogenic differentiation of and mineralization in mesenchymal stem cells. Impaired osteogenic differentiation by GCN5 knockdown is blocked by inhibition of NF-kappaB | Mus musculus |
physiological function | the enzyme GCN5 plays essential roles in various developmental processes, it has a critical function in osteogenic commitment of mesenchymal stem cells. In this role, the histone acetyltransferase activity of GCN5 is not required. Enzyme GCN5 represses nuclear factor kappa B-dependent transcription and inhibits the NF-kappaB signaling pathway. GCN5 is responsible for degradation of RelA. Acetylase activity of GCN5 is dispensable for the regulation of osteogenic differentiation of mesenchymal stem cells | Mus musculus |